These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22763895)

  • 1. HER2 as a therapeutic target in the gastric cancer: is it sufficient?
    Chaturvedi R; Singh AB
    Indian J Gastroenterol; 2012 Jun; 31(3):103-5. PubMed ID: 22763895
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland.
    Collins IM; King F; O'Byrne K
    Ir J Med Sci; 2012 Sep; 181(3):451-2. PubMed ID: 22012551
    [No Abstract]   [Full Text] [Related]  

  • 3. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
    Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
    J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular target for Her2 positive gastric cancer].
    Boku N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2014-20. PubMed ID: 23221049
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab in HER2-positive metastatic gastric cancer: profile report.
    Croxtall JD; McKeage K
    BioDrugs; 2011 Aug; 25(4):257-9. PubMed ID: 21815701
    [No Abstract]   [Full Text] [Related]  

  • 8. Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.
    Bloom KJ; Cote RJ
    Clin Chem; 2011 Jul; 57(7):983-5. PubMed ID: 21558454
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on Gu et al. entitled "Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis".
    Li J; Jing J
    Tumour Biol; 2014 Jul; 35(7):6177. PubMed ID: 24664586
    [No Abstract]   [Full Text] [Related]  

  • 10. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia.
    Choi JH; Han HS; Lee HC; Lee OJ; Kim JT; Lim SN; Lee KH; Kim ST
    Onkologie; 2011; 34(11):621-4. PubMed ID: 22104159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
    Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
    Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):315-9. PubMed ID: 23985265
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.
    Watson S; Validire P; Cervera P; Zorkani N; Scriva A; Lemay F; Tournigand C; Perniceni T; Garcia ML; Bennamoun M; Paye F; Louvet C
    Ann Oncol; 2013 Dec; 24(12):3035-9. PubMed ID: 24114855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab in gastrointestinal cancer.
    Oh DY; Bang YJ
    Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.
    Shitara K; Yatabe Y; Matsuo K; Sugano M; Kondo C; Takahari D; Ura T; Tajika M; Ito S; Muro K
    Gastric Cancer; 2013 Apr; 16(2):261-7. PubMed ID: 22797858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
    Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
    Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.